key: cord-0699889-7ww4hgeu authors: Yang, Li; Yang, Yao; Chen, Hongzhong; Mei, Lin; Zeng, Xiaowei title: Polymeric microneedle‐mediated sustained release systems: Design strategies and promising applications for drug delivery date: 2021-07-24 journal: Asian J Pharm Sci DOI: 10.1016/j.ajps.2021.07.002 sha: b6cedd5cf6f8f8bbb80edd0f70ff8017a5a6ff01 doc_id: 699889 cord_uid: 7ww4hgeu Parenteral sustained release drug formulations, acting as preferable platforms for long-term exposure therapy, have been wildly used in clinical practice. However, most of these delivery systems must be given by hypodermic injection. Therefore, issues including needle-phobic, needle-stick injuries and inappropriate reuse of needles would hamper the further applications of these delivery platforms. Microneedles (MNs) as a potential alternative system for hypodermic needles can benefit from minimally invasive and self-administration. Recently, polymeric microneedle-mediated sustained release systems (MN@SRS) have opened up a new way for treatment of many diseases. Here, we reviewed the recent researches in MN@SRS for transdermal delivery, and summed up its typical design strategies and applications in various diseases therapy, particularly focusing on the applications in contraception, infection, cancer, diabetes, and subcutaneous disease. An overview of the present clinical translation difficulties and future outlook of MN@SRS was also provided. Transdermal drug delivery (TDD), an important substitute for oral administration and hypodermic injections, has attracted great attention. It shows several advantages such as convenient self-administration, reduced systemic side effects, to increase the permeability of SC, such as electroporation, iontophoresis, and ultrasound [5] [6] [7] . However, even with stimulation of external conditions, there are still challenges for larger molecules delivery through the skin, including proteins and genes [8] . Microneedles (MNs), an emerging versatile TDD system to overcome the skin barrier that limits drug penetration efficacy, knock the door of TDD to some extent. They are used to painlessly pierce the SC to remarkably facilitate TDD by generating microchannels for molecules which cannot be delivered across the skin by passive diffusion alone [9] . Since the first introduced of MNs in 1966, MNs have been widely explored to improve the effect of TDD [10] . Until now, MNs can be divided into several categories: solid and hollow MNs, which are used as tools to pierce skin barrier to improve the drug delivery into dermal; coated MNs, which can implant coated drug layers into the skin; polymeric MNs, the cargos can be packaged and transported by host MNs [ 11 ,12 ] . Among them, polymeric MNs are coming to the fore as excellent biocompatibility, outstanding biodegradability, and sufficient drug loading capacity [13] . Nevertheless, initial studies of polymeric MNs mostly focused on rapid drugs delivery [ 14 ,15 ] . There are some drawbacks for rapid release polymeric MNs delivery system: (1) Frequent use of MNs increases chemical burden and irritation to patients; (2) Poor efficacy for therapeutics that require long-term exposure; (3) The release profiles are uncontrollable. With the rapid development of formulation technology, parenteral sustained release formulations are wildly used in clinical practice, such as microparticles (MPs), implants and drug depot [11] . There are some advantages of these drug delivery system. They can reduce frequency of administration, present good patient compliance and show fewer side effects. Especially, taking advantages of sustained release of therapeutics is benefit for diseases that require longterm or repeated administration, such as contraceptives, vaccines and other chronic diseases. Due to its stable drug concentrations in blood and avoiding multiple doses can improve therapeutic effects [16] [17] [18] and patient compliance respectively. However, key issues still need to be solved. Parenteral sustained release formulations usually inject subcutaneously or intramuscularly. These injections lead to problems including pain, generating sharp medical waste, and needle abuse [19] . More importantly, they need professionals to administration, limiting the drug accessibility to patients, especially in developing countries, where suffer severe lack of professional medical staff. In addition, organic solvents for injection can lead to toxicity, such as Eligard, an in situ-forming drug depot which was approved by the FDA [20] . In particular, the uncontrollable shape and size of the depots formed in vivo would further affect drug release [21] . An alternative delivery system to avoid these shortcomings is reshaping the landscape of parenteral sustained release formulations. Polymeric microneedle-mediated sustained release systems (MN@SRS) integrate the advantages of polymeric MNs and sustained release technique, can address these mentioned issues. MN@SRS are minimally invasive, significantly avoid the needle-stick injuries and pain caused by subcutaneously injections. MN@SRS are designed as self-administration, that is, no requirement for skilled medical personnel. More importantly, MN@SRS with different release properties can be fabricated by polymers, which have different degradation manners [9] . The purpose of this review is to highlight the superiorities of MN@SRS in terms of long-term and repeated administration diseases. Specifically, several typical strategies for constructing MN@SRS have been introduced. Furthermore, we summed up the applications of MN@SRS on various diseases therapy, particularly focusing on the applications in contraception, infection, cancer, diabetes, and subcutaneous disease. The clinical translation difficulties at present and development prospect in the future of MN@SRS were also discussed. Four typical categories of MN@SRS have been developed ( Fig. 1 ). One is called long-acting encapsulated or coated MNs. These MNs are only employed as tools to pierce into skin and subsequently implant the pre-loaded cargos. Their sustained release property is acquired by packaged or coated drugs. Another is polymeric-based sustained release MNs, which was fabricated with long-acting polymer that acquire sustained release manner through host MN polymer. Double-sustained release MNs is the third strategy of MN@SRS. These MNs load long-acting packaged drugs in sustained release MNs, in order to obtain a longer sustained release period. Backing layer-based depot MNs is the fourth strategy to realize sustained release of MNs. In this design, drug was loaded in the backing layer as reservoir instead of needles. The needles act as tools to create channels for drug penetration as well as to provide a boost drug loading. MNs based on dissolving polymers such as dextran, sodium chondroitin sulfate, hyaluronic acid (HA), polyvinylpyrrolidone (PVP) are usually combined with nanoparticles (NPs) or MPs to achieve sustained release manner [22] [23] [24] . These MNs dissolve within several seconds/minutes after being inserted into the skin [ 25 ,26 ] Biodegradable polymers hardly dissolve or swell in the skin interstitial fluid (SIF), but can slowly degrade over months. Biodegradable polymers that are appropriate for developing MNs can be divided into two categories: synthetic biodegradable polymers and nature biodegradable polymers. The synthetic ones include poly (lacticco-glycolic) acid (PLGA) and poly (lactic acid) (PLA) [ 30 ,31 ] . The natural biodegradable polymers include chitosan, silk firbroin, and chitin [32] [33] [34] . Drug release rate and duration of this type of polymers are primarily dominated by degradation rate of the biodegradable polymers rather than drug diffusion [35] . In order to obtain a longer sustained release period than long-acting encapsulated MNs, the third strategy of MN@SRS has been designed. These MNs superimposes the sustained The limited drug loading of the MNs may not be able to meet the drug amount required for long-term release. Fortunately, encapsulating cargos into backing layer can greatly enhance drug loading capacity in MNs [1] . In this approach, MNs are usually prepared by swellable or dissolvable polymers. Upon applied into the skin, they are swelled or dissolved after absorb SIF and created channels between drug-loaded backing layer and dermal microenvironment. These MNs act as host to control drug release from baseplate, occasionally, as well as increased drug dose and rapid drug delivery parts [ 39 ,40 ] . Lee There are many methods for preparing polymer-MNs, such as micromolding [42] , droplet-born air blowing (DAB) [43] , drawing lithography [44] , electro-drawing [45] , photolithography [46] , continuous liquid interface production (CLIP) [47] ( Table 1 ) . Among them, micromolding method is the most wildly used in fabrication of MN@SRS due to its easy production, cost-efficiency, and potential for industrialization. Micromolding method consists of six main steps: (1) fabricating MNs male mold; (2) preparing a female MNs mold; (3) casting polymers solution onto female molds and forcing polymers solution into caves by centrifugation or directly pumping polymers solution into caves of female molds; (4) removing bubbles by centrifugation or vacuum; (5) Curing MNs by drying or photocrosslinking; (6) peeling off the MNs from female molds. The most commonly used material for preparing the MN female mold in the step 2 is polydimethylsiloxane (PMDS) based on its excellent stability, good copying ability and low adhesion (beneficial to peel off the MNs from female mold). The drug can be loaded by mixing drug or drug-loaded MPs and NPs with polymer solution, and then forcing mixture into the mold. Voluntary family planning has made a great progress in public health and contraceptive methods allow women to make decisions about the timing and spacing of pregnancies [ 48 ,49 ] . Although great progresses in contraceptive methods, 85 million pregnancies were unintended in 2012, accounting for 40% of all pregnancies worldwide [50] . Many unintended pregnancies are terminated, bringing about 56 million abortions every year [51] . The high incidence of accidental pregnancy leads to serious economic and emotional burden to women and society. Increasing contraceptive options, which better meet the needs of women at diverse stages of their reproductive life cycle, is the key to women's safety and wellbeing. Long-acting contraceptives can provide women with flexible contraceptive protection. To date, there are many long-acting contraceptives on the market, including injectable long-lasting hormonal contraceptives and implantable longacting contraceptives. Injectable long-lasting hormonal contraceptives require trained professionals who are limited in developing counties, and invasive administration, therefore limiting patient access and reducing patient compliance [ 52 ,53 ] . Implantable long-acting hormonal contraceptives can last for years, such as subcutaneous implants and intrauterine devices (IUDs). However, they need administration by even greater trained health care professionals and are even more invasive compared to other methods. Therefore, options for self-administration long-acting contraceptives are limited [ 54 ,55 ] . To response these issues, MN@SRS have been employed to supply a novel option for women contraception. MN@SRS can be self-administrated and maintain long-acting to reduce frequent administration, which greatly increase patient acceptance and compliance. Moreover, MN@SRS are minimally invasive and biodegradable, avoiding needle-stick injury and generating no biohazardous sharps waste. These properties are particularly important in developing countries. He et al. prepared a long-acting MN patch based PLGA for sustained release of etonogestrel (ENG), the third-generation progesterone. A novel preparation method called controllable casting mold technique was introduced to fabricate PLGA MNs and ENG crystals were evenly distributed in the needle tip. By optimization of MN formulations, this MN@SRS can successfully pierce the skin and deliver the entrapped drug, with a drug loading up to 153.0 ± 13.5 μg, achieving sustained release of cargos more than two weeks [18] . In another design, Zhu et al. fabricated a composite LNG-loaded MN@SRS. In this approach, changing the properties of silk protein or formulation of loaded LNG enabled to modify the extendedrelease time of MNs. Specifically, sustained release of LNG maintained 100 d when the drug was directly encapsulated into silk MNs, while release reach up more than a year when the drug was pre-encapsulated in silk MPs prior to load into the MN patches [38] . Despite the MN@SRS described above studies provided new options for long-acting contraception, there are still shortcomings. Obviously, these MNs need to be worn throughout the whole drug release period for several days, months or even years. Prolonged contact of MNs patch with skin may cause irritation, or MNs drop from skin by accident could lead to contraception failure [ 56 ,57 ] . To address these problems, Li and coworkers described a rapidly separable MN platform for long-term delivery of LNG ( Fig. 2 ) . These MNs were made of biodegradable polymers, PLGA, which controlled the release of LNG, and polymer PLA, which increased the mechanical strength of MNs. An air bubble structure was designed between the MN and patch backing, which allowed MNs to efficiently penetrate skin and snap off in five seconds, and successfully relized the rapid separation of MN from backing. Results showed that the MNs implanted into the dermis function as depots for the long-term and systemic delivery of LNG for more than one month [36] . Li and coworkers also developed another rapid separation MN@SRS for long-acting contraception. In this study, rapid separation feature was achieved by an effervescent backing that designed between the MN and adhesive paper. Sodium bicarbonate and citric acid were introduced to the effervescent backing, which would generate carbon dioxide bubbles upon contacting with the SIF after MNs were inserted in the skin. The connection between MNs and backing layer was broken by carbon dioxide bubbles and separation occurred within 1 min. In vivo release result showed that cargos released into medium, which simulated the environment in the body, over 30 d [58] . According to the report published by the Global Cancer Statistics, about 313 million people suffer from superficial cancer. Among them, 0.3 million and over 209 million patients are suffering from melanoma and breast cancer in 2018, respectively [59] . Obviously, superficial tumors have seriously endangered human health, causing psychological burden on patients. Unfortunately, topical administration of drug faces limited drug delivery efficiency while systemic treatments are always accompanied by side effects, and monotherapies remains suboptimal clinical efficacy [60] [61] [62] [63] [64] [65] [66] . Notably, superficial cancers are aggressive and recurrent, repeated treatments are necessary, as a result, chemical burden and the risk of toxicity were increased [ 67 ,68 ] . In terms of superficial tumor therapy, MN@SRS provide unique advantages. MN@SRS directly insert into lesion site of superficial tumor, significantly increase the drug accumulation, and reduce systemic side effects. Besides, sustained release property of MN@SRS avoids repeated treatments, improves convenience of patients and healthcare providers. Moreover, different function cargos loaded into MN@SRS provide synergistic or combined effects. Chemotherapy is one of the most important arsenals to kill tumors [69] . Various versatile carriers greatly improve the anti-tumor effect of chemotherapy drugs [ 70 ,71 ] .For chemotherapy, MN@SRS have been employed for delivery of doxorubicin (Dox), dacarbazine, and other drugs for chemotherapy [72] [73] [74] . Typically, Kim et al. reported a design of a biodegradable MN patch based on porous silicon ( p -Si) with a novel water-soluble backing ( Fig. 3 ) . Dox was covalently linked with p -Si MNs. The water-soluble backing was temporarily used to help insert the MNs into the skin and subsequently dissolved within 1 min, making MNs avoid discomfort and irritation to the patients caused by traditional flexible backing like PDMS backing. Consequently, the p-Si MNs remained implanted inside tissues, gradually hydrolyzed into biocompatible byproducts, continuously released Dox for several days with a controlled rate. The study results showed the MN@SRS exhibit superior anti-tumor efficacy without local skin lesions, which attributed to the minimally invasive and long-last effective drug concentration at the local site based on the sustained release property of MN@SRS [75] . Luo et al. developed a MN@SRS prepared by gelatin methacryloyl (GelMA), an innovative biodegradable material for sustained delivery of Dox. Delivery rates of therapeutics and mechanical properties can be adjusted based on the crosslinking degree of GelMA. The results showed novel GelMA MNs successfully penetrated the skin, and a reverse correlation between sustained release period and crosslinking time could be observed [74] . Cancer immunotherapy is considered as a potentially powerful approach for cancer management [76] [77] [78] . Recently, two treatment pathways exhibit enormous potential in advanced cancer patients. One is adoptive cell therapy (ACT), which is based on directed transfer of T cells into the body to stimulate the immune response against cancer [ 79 ,80 ] . The other is checkpoint blockade, this method treatment with antibodies such as cytotoxic T lymphocyte antigen-4 (CTLA-4) or programmed death-1 (PD-1, or its counter-receptors PD-L1) that block the inhibitory effect [ 81 ,82 ] . However, cancer immunotherapy not only obtains the remarkable effect but also brings non-negligible side effects. For instance, when patients treated with anti-CTLA-4, it might lead to serious adverse events reach up to grade 3 or 4 [ 83 ,84 ] . Therefore, a looming challenge for cancer immunotherapy is avoiding systemic toxicities that prevent immunotherapies from successful clinical transformation. On the other hand, despite anti-PD-1 agents ( αPD11) or anti-PD-L1 agents ( αPDL1) have acquired impressive clinical responses in patients suffered from melanoma, only 30%-40% of patient response to antibodies blocking PD1/PDL1 because of the presence of intrinsic or acquired resistance of immunotherapies [85] [86] [87] . Combination therapy of antibodies blocking PD1/PDL1 with other immune activation agent could achieve synergistic anti-tumor effect [88] [89] [90] . As a result, a series of clinical trials of combination therapy are underway [91] . Unfortunately, the protocol of most current clinical trials consists of repeated intratumoral injections, that may lead to the destruction of the tumor microenvironment and blood vessels, increasing the risk of tumor metastasis and penetration [92] [93] [94] [95] . To response challenges mentioned above, immunotherapy mediated by MN@SRS shows broad prospects, including (1) directly local administration of MN@SRS into lesion sites, the drug is preferentially reserved at the injection site, which allow lower drug concentration than systemic administration; (2) MN@SRS can locally control the release of drug, confine therapeutics to target lesion sites, reaching full curative potential of drug by avoiding debilitating toxicities and multiple intratumoral injections; (3) Multiple drugs can be loaded into MN@SRS to obtain synergistic effect and enhance anti-cancer efficacy. (4) MN@SRS could overcome the SC barrier and insert into dermis, where are plenty of dermal dendritic cells (DCs) that play important role in immunomodulation. Therefore, MN@SRS are approaches to enhance local immunotherapy for superficial tumors. Wang et al. loaded αPD1 into a MN patch for local and controlled delivery of αPD1. αPD1 and glucose oxidase (GOx) were loaded into the pH-sensitive dextran NPs. GOx transformed the blood glucose to gluconic acid during MNs were inserted into skin. The acid environment promoted the dissolution of NPs and following release of packaged αPD1. Compared with control groups (MNs without GOx or intratumoral injection of free αPD1), this MN patch produced strong immune responses [85] . However, tumor cells can catalyze a series of immunosuppressive molecules. For example, indoleamine 2,3-dioxygenase (IDO), which can restrict T cells functions [ 96 ,97 ] . Thus, monotherapy with immunologic drugs obtains limited immunotherapy clinical benefit [98] . To overcome this problem, Ye and coworkers employed MNs for sustained delivery of αPD1 combined with an inhibitor of IDO, 1-methyl-DL-tryptophan (1-MT). Both cargos achieved sustained release for over 48 h. The synergistic and sustained delivery of 1-MT and αPD1 by MNs exhibited potent anti-cancer potential and prolonged anti-tumor efficacy [99] . Ye et al. developed a MN@SRS system encapsulated inactive B16F10 melanoma lysates and melanin ( Fig. 4 ) . In this study, melanoma lysates were gradually release from MNs for over five days, subsequently facilitated immune response. At the same time, melanin generated immunogenic substrates through local release of heat, which was transferred via nearinfrared (NIR), further enhanced tumor immune activation. In vivo results indicated that the MNs successfully hampered tumor engraftment in prophylactic models and achieved prolonged tumor suppressor efficacy in tumor-bearing mice [100] . Zhou et al. designed a transfersome/MNs complex system to co-deliver pembrolizumab ( αPD1), tumor associated antigen (TAA) and adjuvant poly I:C. In this study, HA-GMS-αCD40 was introduced to modify the surface of transfersome to endue target capacity to DCs. The results showed the MN@SRS with controlled release of all cargos exhibited great potential in tumor immunotherapy [87] . Gene therapy has been wildly applied to treatment of disease, including cancer therapy [101] [102] [103] . With the successful of LUXTURNA®, a FDA approved gene therapy for biallelic RPE65 mutation-associated retinal dystrophy [104] , many strategies have been developed to explore effective gene delivery. Unfortunately, there are still some challenges. Appropriate delivery carriers and suitable delivery routes play important roles in gene delivery [105] . Based on previous studies, MN@SRS provide a new platform of gene delivery [ 106 ,107 ] . Typically, Qu et al. presented a MN patch based on GelMA for local and sustained delivery of plasmid DNA (pDNA) ( Fig. 5 ) . Intracellular delivery of the pDNA was achieved by encapsulating it into poly ( β-amino ester) (PBAE) NPs. The MN@SRS showed robust transfection effect of the nucleic acid cargo both in vitro and in vivo [108] . DeMuth's group constructed a releasable PEM coated polymeric MNs patch. On this base, they loaded DNA and adjuvants into the MNs to achieve continuous release of cargos from day to weeks, strengthening immune response [29] . Diabetes is a chronic disease accompanied by disorders of blood glucose metabolism [109] [110] [111] . According to the reports published from the International Diabetes Federation (IDF), approximately 463 million people suffered from diabetes in 2019, and it is estimated the number would reach up to 700 million by 2045. Obviously, the situation is worrisome [3] . Diabetes can be divided into three categories: type 1 diabetes (T1D), type 2 diabetes (T2D) and gestational diabetes (GD). T1D is caused by less secretion of insulin while T2D is usually caused by insulin resistance [112] . For T1D and advanced T2D, insulin is the most used drug to effectively control blood glucose levels (BGLs) [113] [114] [115] . To date, there are several insulin formulations available on the market [ 116 ,117 ] . Usually, these formulations are administrated by subcutaneous injection mediated by hypodermic needle or pump [115] . Frequent injections lead to poorly patient compliance [ 118 ,119 ] . In recent years, new choices have been emerged in treatment of T2D, including glucagon-like peptide-1 (GLP-1) agonists/analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors [120] . The most representative drug is longacting exenatide, Bydureon, which has been approved by FDA and European Medicines Agency (EMA). Bydureon is microsphere based on PLGA for once-weekly subcutaneous injection [ 121 ,122 ] . Long-acting exenatide greatly reduces frequency of injection, but injection pain, needle phobia and adverse reactions at the injection site are still inevitable. In response to these challenges, polymeric MNs as a dramatic delivery system have been wildly explored for insulin delivery [123] [124] [125] . Based on the previous studies, insulin maintained biological activity during the preparation and storage period of polymeric MNs, which means insulin encapsulated into polymeric MNs do not require cold chain to transport and storage, and can be used conveniently by patients for long-term [126] [127] [128] . Moreover, the BGLs in animal models were effective controlled by insulin MNs have been demonstrated [129] [130] [131] [132] . Nonetheless, these traditional polymeric MNs release insulin with uncontrolled manner, which is not conductive to manage patient's BGLs [ 133 ,134 ] . The limited drug loading efficacy of traditional polymeric MNs would fail to meet the requirement of long-term exposure drug dose [134] . To solve these problems, MN@SRS were designed for sustained delivery of insulin with a controlled manner. In particular, the integrated system based on MN@SRS can deliver cargos for initial quick release and subsequent sustained release, with flexible application for diabetes patients. Moreover, backing layer-based MN@SRS significantly increase drug loading capacity of MNs, and successfully avoid limited loading efficacy of drugs which need longterm exposure. Donnelly et al. prepared hydrogel MNs to enhance transdermal delivery efficiency and drug loading of macromolecules like insulin. Interestingly, the MNs themselves contained with no drugs, but instead, attached patch acted as drug reservoirs. After application, the MNs rapidly absorbed skin SIF to produce continuous and un-blocked hydrogel conduits. These hydrogel conduits connected attached patch drug reservoirs with dermal microcirculation, resulting in controlled drug release from reservoirs. This MN@SRS platform significantly improved drug loading efficacy of insulin to 5 mg/cm 2 with a release period over 24 h [135] . Similarly, Zhu and coworkers utilized backing layer as depot for sustained release of insulin. The MN@SRS showed approximative relative pharmacological availability and more lasting and stable hypoglycemic effect compare to injection [40] . Che et al. constructed smart MNs combined boronate-containing hydrogel with silk fibroin. Acute, long-lasting, and glucoseresponsive insulin delivery properties were integrated into the smart MNs ( Fig. 6 ) . Silk fibroin was introduced to enhance mechanical strength while the boronate-containing hydrogel possessed glucose-responsive ability, providing insulin with diffusion-controlled release for days. Thus, the smart MNs provided a potential choice to solve a series of unsatisfied medical needs in the treatment of diabetes patients [136] . In the past decades, millions of people from all over the world are threatened by infectious diseases, causing an enormous burden on public health and global economies [137] [138] [139] . In fact, the emerging coronavirus disease (COVID-19) clearly revealed the huge challenges of pandemic to public health [140] [141] [142] . To date, vaccination has been the main method of effective prevention and treatment of infectious diseases. According to the data estimated by the world health organization, vaccination protected 2.5 million children from infectious deaths each year [143] . Skin is an attractive immune organ for delivering vaccine because of its easily accessible character and rich network of DCs such as langerhans cells (LCs) and macrophages [144] [145] [146] . These specialized DCs possess strong antigen presentation capability. They transfer to the skin draining lymph nodes (DLNs) and then present processed antigens of T and B lymphocytes to induce pathogen-specific protective immunity [147] [148] [149] [150] . Unfortunately, most of vaccines are delivered by hypodermic needle injection because of skin barrier layer. Palpably, hypodermic needle injection brings a serious of problems including injection pain, needle stick injuries and time consuming [151] . Importantly, traditional immunization causes rapid antigen clearance, and one-time injection can only activate the immune system but fails to elicit protective immunity [ 152 ,153 ] . Based on the previous studies, repeated injections or sustained delivery of antigens via implanted miniosmotic pumps enhanced the humoral responses compared to traditional immunization, own to increased antigen availability [154] [155] [156] [157] . However, immunizations through osmotic pump implantation or multiple injections are impractical for prophylactic vaccination. Furthermore, cold chain transportation and storage increase the cost of vaccines. Owing to these challenges, MN@SRS are wildly used as a pain-less and self-administration method for vaccines delivery. MN@SRS control vaccine kinetics, resulting in continuous exposure of lymphoid tissues to vaccine antigens with promotional humoral immunity. In addition, MN@SRS are dry formulations that improved the stability of vaccines, thereby eliminating the problems caused by cold chain requirements during vaccine transportation and storage. Moreover, the self-administration potential of MN@SRS is meaningful for prophylactic vaccination, especially for areas where there is lack of professional medical personnel. Motivated by these merits of MN@SRS, Boopathy et al. designed a silk fibroin-based MN patch for continuous delivery of HIV vaccine. Poly (acrylic acid) (PAA) was chosen as the material of dissolving backing layer. Once the MN@SRS were applied into the skin, the backing layer made by PAA rapidly dissolved, allowing silk needle tips to separate from patch and implant into the skin. With the swelling and hydrolysis of silk matrix, the entrapped vaccine was released over two weeks. In vitro release studies showed the structure of antigen released from the MNs maintained structural integrity. Immune response by MNs was enhanced 1300-fold higher antibody titers than equivalent bolus injections at 1-month post-boost, which was due to sustained release vaccines from MNs [158] . Interestingly, DeMuth et al. also prepared a silk fibroinbased separation MN for programmable vaccine release and enhanced immunogenicity in transcutaneous immunization ( Fig. 7 ) . The PAA acted as a separation layer, both silk fibroin needle tips and PAA separation layer loaded a model drugvaccine ovalbumin (OVA). After a short application of the MN patch into the skin, the PAA layer quickly dissolved to provide a bolus of OVA. At the same time, a long-release silk fibroin reservoir was implanted into the skin to within 1-2 weeks low-level sustained skin vaccine release [159] . Similarly, Chen et al. employed chitosan-PLA based rapidly detachable MNs to deliver OVA. After applied into skin, OVA-loaded chitosan needle tips were separated from the PLA sporting array by soluble PVP coated layer dissolving. The implanted needle tips allow the antigen to release constantly at insert site for at least 14 d, inducing a robust immune response for over 6 weeks [160] . Skin diseases caused by bacteria, fungi, and viruses have been wildly explored due to their high prevalence and serious consequence [161] [162] [163] [164] . As reported, they are the fourth leading cause of disability globally in 2013 excluding mortality, affecting over 3% of worldwide population [ 165 ,166 ] . Until now, polymeric MNs have been diffusely employed to treat skin diseases such as hypertrophic scar, acne and actinic keratosis [167] [168] [169] . For example, Lin et al. designed polymeric MNs based on HA to reduce abnormal scar [170] . Zhang and coworker prepared poly (ionic liquids) (PILs) based MNs for acne infections treatments [171] . Around 20-25% of the worldwide population affected by skin fungal infection, also known as mycosis, especially those patients with AIDS and cancer with compromised immune systems [ 172 ,173 ] . Completely eliminating deep cutaneous mycosis is still a big challenge [174] [175] [176] [177] . The key point to cure deep cutaneous mycosis is effectively deliver localized and sustained release drugs into infected deep tissue, which can completely kill the fungi in chronic infection and successfully prevent the development of drug resistance [ 178 ,179 ] . To tackle these issues, MN@SRS provide a promising choice for the treatment of deep fungal infection. Zan et al. prepared a MN patch consists with chitosan-polyethylenimine (CP) and Amphotericin B (AB) to treat deep cutaneous mycosis ( Fig. 8 ) . CP acted as biocompatible polymer as well as antimicrobial, which produced synergistic antibacterial effect with AB. High permeability of therapeutics by piercing the barrier of skin, localized and sustained release of therapeutic contributed to superior antifungal infection effectiveness of the MN@SRS compared with conventional cream application [180] . Another type of skin disease is skin wounds caused by various reasons, among them, chronic wounds are a global healthcare challenge, causing serious personnel and economic burden [181] . Chronic wounds mostly occur in diabetic and bedbound patients, they may maintain inflammation period for months or years, such skin damage can be life-threatening if it is not healed in time [ 182 ,183 ] . One of the current challenges in the treatment of chronic wounds is bacterial infection. The use of antibacterial dressings or prophylactic antibiotics has been successful in reducing wound infections to some extent, however, they usually reduce the speed of wound healing and promote the development of drug resistance [184] . The other challenge is chronic wounds are usually accompanied by eschar, therapeutic drugs need to pass through the eschar to reach the healthy cells below. It is well known that the localized delivery of exogenous growth factors and antiinflammatory factors can improve the quality of wound healing, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) [ 185 ,186 ] . Unfortunately, these biological factors need the right concentration at specific time points to be effective. Therefore, smart drug delivery systems based on stimuli-responsive materials have been developed, such as hydrogel [187] . These materials can response to various wound environments to release loaded drugs. But there is still a problem worthy of attention: whether these drug delivery systems can deliver drugs through eschar and effectively accumulate in healthy cells below the eschar. To address the issues, MN@SRS show the potential for chronic wound treatment. MN@SRS are micro-invasive, they can pierce the eschar and effectively deliver drugs to healthy cells. They can also destroy the biofilm formed in bacterial infections, which is a protective barrier for bacteria, obtain better antibacterial effects. More importantly, active and smart drug delivery strategies integrated with MN@SRS can easily comply with the dynamic pathophysiological conditions of chronic wounds and further enhance wound healing duo to their controlled drug release property. For example, Chi et al. developed a chitosan MN patch integrated with VEGF-loaded temperature sensitive hydrogel for promoting wound healing. When the MN applied to the wound, the increased temperature caused by the inflammation reaction degraded the hydrogel and intelligently released VEGF [188] . The application field of MN@SRS is broad. In this review article, we surveyed typical articles instead of all the related studies to exhibit extensive therapeutic applications of MN@SRS. Altogether, MN@SRS that combined MNs patch with sustained release drug delivery system ingeniously, were viewed as a successfully platform to deliver drugs and vaccines. MN@SRS can be also used as synergistic therapies, realizing the strategies of "two birds with one stone". The self-administration potential of MN@SRS increased patient's access to medications and further enhanced patient compliance. In this regard, women who need contraception and HIV-infected patients benefit greatly. They both require long-acting formulations that are convenient for self-administration to reduce the pill burden. Especially for AIDS patients, they are often unwilling to expose the fact that they are sick to other people. On the other hand, MN@SRS directly deliver vaccines into skin tissue where has rich immune cells, subsequently generating robust immune stimulation due to the durable release of vaccines, which is beneficial for immunotherapy. In addition, MN@SRS can avoid cold chain transportation and address storage difficulties of unstable drugs, such as peptides, proteins and nucleosides, reducing the cost of drugs. Even though MN@SRS exhibited great potential for improving therapeutic efficacy, practical clinical translation is still in their infancy, and patients do not really get the benefits from this novel platform. In this sense, there are still some issues need to be solved. Firstly, the cooperation between academia, industry and regulatory authorities must be strengthened, not only to develop new products, but also to boost explore of new good manufacturing practices (GMP) and realize industrialization. Furthermore, MN@SRS are a new TDD system instead of substitute of conventional transdermal patches, therefore, their mechanism of action and the safety of materials are crucial. Most of MN@SRS are made of FDAapproved polymers, such as PLA, PLGA, etc. Although the safety of these materials has been established for a long time, they have never been administered intradermally. The routes of metabolism and elimination of these materials and the safety of deposition into the skin for a long-term need to be investigated. Unlike conventional transdermal or topical drug delivery systems, MN@SRS will encounter viable skin cells, whether the MN@SRS keep sterile is another question worth considering. All these factors will delay the commercialization of MN@SRS. Also, due to the complexity of the sustained release compared with bolus release, the release kinetics of MN@SRS need further explore. Nevertheless, with the success of MNs on an industrial scale, for example, Zosano Pharma Corporation (USA) announced the acceptance of their New Drug Application (NDA) by the FDA for their product Qtrypta, a zolmitriptan-loaded MN patch for the treatment of migraine headaches [189] . MN@SRS should also be available in the clinic in the future. Qtrypta is an array of close to two thousand drug-coated titanium MNs, which is mounted on the skin-facing surface of a backing that resembles an adhesive bandage. The length of each individual MN is about 3 times the width of a human hair. When the MN patch is applied, the MNs penetrate the outermost layer of the epidermis. The coated zolmitriptan is dissolved by SIF and absorbed rapidly into the bloodstream. The shallow depth of penetration limits the likelihood of stimulating sensory nerve endings and causing pain. To this end, impressive advance in this area has been made by Vaxess Technologies (USA), its proprietary MIMIX TM therapies based on technology originally developed at Tufts University and MIT. MIMIX TM therapies are silk fibroin-based MN@SRS for oncology and infectious disease development. This technology is utilizing the natural properties of silk fibroin to obtain the most effective delivery profiles of various drugs and achieve better treatment effect. The silk fibroin-based MN@SRS was fabricated by micromolding method, specifically, silk fibroin was used as needle tip material and PAA played a role as separation layer. After the MN patch is applied on the skin, PAA layer dissolved quickly, silk fibroin-based needle tips were implanted into skin act as drug reservoir to achieve long-term treatment. If these products successful approved by FDA, which will represent a key milestone for the field. The authors declare no conflict of interest. Long-acting microneedles: a progress report of the state-of-the-art techniques Transdermal drug delivery Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery Polymeric microneedles for controlled transdermal drug delivery Electroporation-based technologies for medicine: principles, applications, and challenges Transdermal iontophoresis of flufenamic acid loaded PLGA nanoparticles Current status and future potential of transdermal drug delivery Approaches for breaking the barriers of drug permeation through transdermal drug delivery Recent advances in the design of polymeric microneedles for transdermal drug delivery and biosensing Polymeric microdevices for transdermal and subcutaneous drug delivery Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine Infusion pressure and pain during microneedle injection into skin of human subjects Microneedles as the technique of drug delivery enhancement in diverse organs and tissues H 2 O 2 -responsive vesicles integrated with transcutaneous patches for glucose-mediated insulin delivery Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease Sodium hyaluronate/chitosan composite microneedles as a single-dose intradermal immunization system Intradermal implantable PLGA microneedles for etonogestrel sustained release Microarray patches: potentially useful delivery systems for long-acting nanosuspensions An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots In situ forming implants-an attractive formulation principle for parenteral depot formulations Incidence of low bioavailability of leuprolide acetate after percutaneous administration to rats by dissolving microneedles Feasibility of microneedles for percutaneous absorption of insulin Near-infrared responsive 5-fluorouracil and indocyanine green loaded MPEG-PCL nanoparticle integrated with dissolvable microneedle for skin cancer therapy IgG-loaded hyaluronan-based dissolving microneedles for intradermal protein delivery Fabrication of a novel partially dissolving polymer microneedle patch for transdermal drug delivery Localised and sustained intradermal delivery of methotrexate using nanocrystal-loaded microneedle arrays: potential for enhanced treatment of psoriasis formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension Polymer multilayer tattooing for enhanced DNA vaccination Fabrication of microneedle using poly lactic acid sheets by thermal nanoimprint Hydrogel swelling as a trigger to release biodegradable polymer microneedles in skin Chitin microneedles for an easy-to-use tuberculosis skin test Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination Extended release formulations using silk proteins for controlled delivery of therapeutics Fabrication of silk microneedles for controlled-release drug delivery Rapidly separable microneedle patch for the sustained release of a contraceptive Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design Silk fibroin microneedle patches for the sustained release of levonorgestrel Hydrogel-forming microneedles prepared from "super swelling" polymers combined with lyophilised wafers for transdermal drug delivery Combined silk fibroin microneedles for insulin delivery Dissolving microneedles for transdermal drug delivery Fabrication of a novel partially dissolving polymer microneedle patch for transdermal drug delivery Droplet-born air blowing: novel dissolving microneedle fabrication Drawing lithography for microneedles: a review of fundamentals and biomedical applications Electro-drawn polymer microneedle arrays with controlled shape and dimension A photolithographic approach to polymeric microneedles array fabrication Single-step fabrication of computationally designed microneedles by continuous liquid interface production Family planning and the post-2015 development agenda Intended and unintended pregnancies worldwide in 2012 and recent trends Declines in unintended pregnancy in the United States Abortion incidence between 1990 and 2014: global, regional, and subregional levels and trends Synchronic release of two hormonal contraceptives for about one month from the PLGA microspheres: in vitro and in vivo studies Long-acting injectable contraception with depot medroxyprogesterone acetate Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant Young women's experiences of side-effects from contraceptive implants: a challenge to bodily control A self-adherent, bullet-shaped microneedle patch for controlled transdermal delivery of insulin Materials science dry solution to a sticky problem Long-acting reversible contraception by effervescent microneedle patch Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Engineered nanoparticles for drug delivery in cancer therapy The interplay of immunotherapy and chemotherapy: harnessing potential synergies Metronomic chemotherapy and immunotherapy in cancer treatment Delivery technologies for cancer immunotherapy Challenges and strategies in anti-cancer nanomedicine development: an industry perspective A multifunctional nanoplatform against multidrug resistant cancer: merging the best of targeted chemo/gene/photothermal therapy Mussel-inspired polydopamine: the bridge for targeting drug delivery system and synergistic cancer treatment Malignant melanoma Applications of surface modification technologies in nanomedicine for deep tumor penetration Progress and perspective of microneedle system for anti-cancer drug delivery Polydopamine-modified black phosphorous nanocapsule with enhanced stability and photothermal performance for tumor multimodal treatments Versatile polydopamine platforms: synthesis and promising applications for surface modification and advanced nanomedicine Microstereolithography and characterization of poly(propylene fumarate)-based drug-loaded microneedle arrays Fabrication and characterization of thiolated chitosan microneedle patch for transdermal delivery of tacrolimus Biodegradable gelatin methacryloyl microneedles for transdermal drug delivery Bioresorbable, miniaturized porous silicon needles on a flexible water-soluble backing for unobtrusive, sustained delivery of chemotherapy Cancer immunotherapy comes of age Delivering safer immunotherapies for cancer Materials for immunotherapy Engineered T cells: the promise and challenges of cancer immunotherapy Adoptive cell transfer as personalized immunotherapy for human cancer PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations The future of immune checkpoint therapy Combined nivolumab and ipilimumab or monotherapy in untreated melanoma Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody Combined nivolumab and ipilimumab or monotherapy in untreated melanoma Reverse immune suppressive microenvironment in tumor draining lymph nodes to enhance anti-PD1 immunotherapy via nanovaccine complexed microneedle Bone morphogenetic protein 7 promotes resistance to immunotherapy Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer Adaptive, and acquired resistance to cancer immunotherapy Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy IDO expression by dendritic cells: tolerance and tryptophan catabolism Targeting the indoleamine 2,3-dioxygenase pathway in cancer Resisting resistance to immune checkpoint therapy: a systematic review Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors A melanin-mediated cancer immunotherapy patch Nucleic acid delivery into skin for the treatment of skin disease: proofs-of-concept, potential impact, and remaining challenges RNA interference in the clinic: challenges and future directions Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination FDA documents reveal the value of a costly gene therapy Gene therapy: trials and tribulations Microneedle arrays coated with charge reversal pH-sensitive copolymers improve antigen presenting cells-homing DNA vaccine delivery and immune responses Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy Biodegradable microneedle patch for transdermal gene delivery American Diabetes AssociationDiagnosis and classification of diabetes mellitus Insulin delivery systems combined with microneedle technology Preparation, properties and challenges of the microneedles-based insulin delivery system The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern Insulins today and beyond Therapies for type 1 diabetes: current scenario and future perspectives Insulin delivery methods: Past, present and future Recent advances in insulin therapy Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery Microneedles for transdermal delivery of insulin Controlled release systems for insulin delivery The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany Insulin delivery systems combined with microneedle technology Advances in transdermal insulin delivery Preparation, properties and challenges of the microneedles-based insulin delivery system The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin Poly-gamma-glutamic acid microneedles with a supporting structure design as a potential tool for transdermal delivery of insulin Polymer microneedles fabricated from alginate and hyaluronate for transdermal delivery of insulin Dissolving microneedle patches for transdermal insulin delivery in diabetic mice: potential for clinical applications Two-layered dissolving microneedles formulated with intermediate-acting insulin Microneedles fabricated from alginate and maltose for transdermal delivery of insulin on diabetic rats Near-infrared light triggered and separable microneedles for transdermal delivery of metformin in diabetic rats Biologically inspired and chemically derived methods for glucose-responsive insulin therapy Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery Microneedle-array patch fabricated with enzyme-free polymeric components capable of on-demand insulin delivery The challenge of emerging and re-emerging infectious diseases Emerging human infectious diseases and the links to global food production Emerging infectious diseases: threats to human health and global stability The socio-economic implications of the coronavirus pandemic (COVID-19): a review Disease and healthcare burden of COVID-19 in the United States How will country-based mitigation measures influence the course of the COVID-19 epidemic? Nanoparticle vaccines against infectious diseases Transdermal immunomodulation: principles, advances and perspectives The skin surface as antimicrobial barrier: present concepts and future outlooks The immunological anatomy of the skin Dendritic-cell-based therapeutic cancer vaccines Human skin dendritic cells in health and disease Ueno Harnessing human dendritic cell subsets to design novel caccines Tailored immunity by skin antigen-presenting cells Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system Old and new vaccine approaches Liposomes and ISCOMs envelope trimers are highly restricted in specificity Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses Elicitation of robust Tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization Implantable microneedles with an immune-boosting function for effective intradermal influenza vaccination Prevalence and associated factors of skin diseases in aged nursing home residents: a multicentre prevalence study A Therapeutic microneedle patch made from hair-derived keratin for promoting hair regrowth Clinical analysis of deep cutaneous mycoses: a 12-year experience at a single institution Advances in antimicrobial microneedle patches for combating infections Global skin disease morbidity and mortality an update from the global burden of disease study Hyaluronic acid-mediated drug delivery system targeting for inflammatory skin diseases: a mini review Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases ROS-responsive microneedle patch for acne vulgaris treatment Dissolving triamcinolone-embedded microneedles for the treatment of keloids: a single-blinded intra-individual controlled clinical trial Strategy for hypertrophic scar therapy: improved delivery of triamcinolone acetonide using mechanically robust tip-concentrated dissolving microneedle array Active pharmaceutical ingredient poly(ionic liquid)-based microneedles for the treatment of skin acne infection Epidemiological trends in skin mycoses worldwide Global warming will bring new fungal diseases for mammals Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists Topical delivery of drugs for the effective treatment of fungal infections of skin Pre-existing liver disease and toxicity of antifungals Treatment of chromoblastomycosis Combating drug-resistant fungi with novel imperfectly amphipathic palindromic peptides Mechanisms of antifungal drug resistance Antimicrobial microneedle patch for treating deep cutaneous fungal infection Microneedle arrays for the treatment of chronic wounds Reconciling increasing wound care demands with available resources Prediction and monitoring the therapeutic response of chronic dermal wounds Drug delivery systems and materials for wound healing applications Topical advances in wound care Harnessing growth factors to influence wound healing Dual-crosslinked mussel-inspired smart hydrogels with enhanced antibacterial and angiogenic properties for chronic infected diabetic wound treatment via pH-responsive quick cargo release Antibacterial and angiogenic chitosan microneedle array patch for promoting wound healing Microarray patches: poking a hole in the challenges faced when delivering poorly soluble drugs We are grateful for the financial support from the National Natural Science Foundation of China ( 32071342 and 31922042 ), Guangdong Special Support Program ( 2019TQ05Y209 ), and the Fundamental Research Funds for the Central Universities ( 19ykzd31 ). reference